Can Taking Metformin Early After COVID-19 Reduce the Risk of Long COVID? What a New Study Found

Parenting Patch Staff

Metformin, a common type 2 diabetes drug, is being studied as a way to lower the risk of long COVID. BY: UNSPLASH

Adults who were prescribed the diabetes drug metformin within a week of a COVID-19 diagnosis were less likely to develop long COVID or die over the following six months, per a new analysis of health records.

The study, published October 29, found that metformin prescribed within a week of documented infection was associated with a 53 percent lower risk of long COVID or death over six months, compared with other medications.

What Did the Study Find?

Metformin is not approved for COVID-19 or long COVID and doctors advise patients to talk with a health care provider before taking it. BY: UNSPLASH

The research team, led by Dr. Carolyn Bramante of the University of Minnesota, used electronic health records to mimic a clinical trial. They compared patients who received a prescription within days 0 to 6 of infection against those given comparator drugs.

They counted long COVID and death together so that deaths would not skew the results. CIDRAP also reported on the findings. The work is reportedly observational. It showed an association and not the proof that the drug caused the benefit.

What Did Earlier Trials Say?

Researchers used electronic health records to compare patients prescribed metformin within a week of a COVID-19 diagnosis with those given other drugs. BY: UNSPLASH

The findings add to a growing body of research. A 14-day course of metformin was shown to prevent long COVID in the COVID-OUT trial, published in The Lancet Infectious Diseases. It enrolled 1,200 adults. Patients who started the drug within three days of symptom onset had a 63 percent lower risk.

A separate randomized trial in Clinical Infectious Diseases reportedly followed nearly 3,000 outpatients with mild to moderate COVID-19. Those who got metformin had a 50 percent lower risk of a clinician-diagnosed case of long COVID. That trial’s main endpoint, any COVID symptoms at day 180, did not meet its efficacy threshold.

Not every result has been as strong. A Stanford-led study of 53,332 adults with type 2 diabetes found that those already taking metformin had a 39 percent lower risk of death in the year after infection. The link to long COVID was smaller and not statistically significant.

Why It Might Work and What Are Safety Options

Randomized trials suggest that starting metformin early may lower the risk of long COVID, though results vary between studies. BY: UNSPLASH

Researchers have offered several explanations. Bramante has said metformin’s antiviral properties likely helped prevent long COVID in trial participants. Other authors pointed to the drug’s anti-inflammatory effects beyond lowering blood sugar. The exact mechanism has not been settled.

University of Minnesota researchers said metformin taken during acute COVID-19 is safe and does not cause low blood sugar or serious side effects.

Researchers believed metformin’s antiviral and anti-inflammatory effects may play a role, but the exact mechanism has not been settled. BY: UNSPLASH

Important gaps remain. Researchers don’t know whether metformin can prevent long COVID in children. They also don’t know whether it can treat long COVID in people who already have it.

Timing appears to matter. The strongest results came when treatment started within days of infection, so the drug would have to be prescribed quickly.

Metformin is inexpensive and widely available, but it is a prescription drug that is not approved for COVID-19 or long COVID. People were advised to talk with their doctor rather than seek it out on their own.

Have a question about this article or other Parenting Patch content?